Biogen Inc. (BIIB)
NASDAQ:BIIB
Want to see BIIB full AI Analyst Report?
BIIB Stock Chart & Stats
$177.35
-$1.36(-0.89%)
At close: 4:00 PM EST
$177.35
-$1.36(-0.89%)
Day’s Range― - ―
52-Week Range$121.05 - $205.97
Previous CloseN/A
Volume268.56K
Average Volume (3M)1.16M
Market Cap
$27.88B
Enterprise Value$32.12B
Total Cash (Recent Filing)$4.28B
Total Debt (Recent Filing)$6.56B
Price to Earnings (P/E)21.0
Beta0.53
Next Earnings
Jul 16, 2026EPS Estimate
3.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.37
Shares Outstanding147,637,120
10 Day Avg. Volume1,052,024
30 Day Avg. Volume1,161,671
Financial Highlights & Ratios
PEG Ratio-0.95
Price to Book (P/B)1.41
Price to Sales (P/S)2.63
P/FCF Ratio12.59
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue3.26
Enterprise Value/Gross Profit4.67
Enterprise Value/Ebitda11.51
Forecast
1Y Price Target
$219.00Price Target Upside23.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering26
EPS Forecast (FY)14.62
Revenue Forecast (FY)$9.90B
Bulls Say, Bears Say
Bulls Say
Cash Generation & Balance SheetBiogen’s strong free cash flow and sizable liquidity provide durable financial flexibility. Robust FCF and a modest net-debt position support sustained R&D funding, commercial launches, opportunistic M&A and planned deleveraging, reducing financing risk over the next several quarters.
Late‑stage Pipeline Progress (diranersen)Compelling Phase 2 diranersen data that combine biomarker reductions with cognitive signal materially de-risks a tau-directed program. Advancing to registrational development converts early-stage promise into a tangible late-stage asset with multi-year potential in Alzheimer’s, improving long-term product optionality.
Strategic Portfolio Expansion (Apellis)Acquiring Apellis adds two commercial ophthalmology products and established nephrology infrastructure, diversifying revenue and accelerating felzartamab readiness. The deal enhances near-term revenue base and creates cross-therapeutic commercial scale that supports durable growth beyond core neurology.
Bears Say
Regulatory & Clinical Binary RiskKey regulatory review extensions and high-stakes readouts underscore binary outcomes for pivotal assets. Protracted or adverse regulatory decisions on lecanemab or other novel modalities can materially alter uptake timelines and revenue trajectories, keeping program risk elevated over the medium term.
Top-line Volatility & Modest Recent GrowthRevenue has been uneven historically, with declines across 2022–2024 and only modest growth recently. This pattern signals dependence on a few growth products and lumpy commercial timing, which complicates predictable revenue scaling and makes long-term forecasting and margin planning more uncertain.
Near-term Acquired Charges & Deal FinancingMaterial acquired IPR&D charges and incremental borrowings for the Apellis deal create near-term EPS headwinds and raise leverage temporarily. Even if accretive later, these items pressure margins and capital allocation in 2026–2027 and constrain flexibility for other investments until deleveraging occurs.
Biogen News
BIIB FAQ
What was Biogen Inc.’s price range in the past 12 months?
Biogen Inc. lowest stock price was $121.05 and its highest was $205.97 in the past 12 months.
What is Biogen Inc.’s market cap?
Biogen Inc.’s market cap is $27.88B.
When is Biogen Inc.’s upcoming earnings report date?
Biogen Inc.’s upcoming earnings report date is Jul 16, 2026 which is in 42 days.
How were Biogen Inc.’s earnings last quarter?
Biogen Inc. released its earnings results on Apr 29, 2026. The company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $3.054 by $0.516.
Is Biogen Inc. overvalued?
According to Wall Street analysts Biogen Inc.’s price is currently Undervalued.
Does Biogen Inc. pay dividends?
Biogen Inc. does not currently pay dividends.
What is Biogen Inc.’s EPS estimate?
Biogen Inc.’s EPS estimate is 3.18.
How many shares outstanding does Biogen Inc. have?
Biogen Inc. has 147,637,120 shares outstanding.
What happened to Biogen Inc.’s price movement after its last earnings report?
Biogen Inc. reported an EPS of $3.57 in its last earnings report, beating expectations of $3.054. Following the earnings report the stock price went up 5.998%.
Which hedge fund is a major shareholder of Biogen Inc.?
Currently, no hedge funds are holding shares in BIIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biogen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$219.00 (23.48% Upside)
$219.00 (23.48% Upside)
Blogger Sentiment
Bullish
BIIB Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 590.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.63%
12-Months-Change
Fundamentals
Return on Equity
7.55%
Trailing 12-Months
Asset Growth
5.17%
Trailing 12-Months
Company Description
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
BIIB Company Deck
BIIB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple clear commercial and pipeline strengths — notably strong EPS growth, $851M in growth‑product revenue (up 12%), LEQEMBI growth (up 74% YoY) and a robust development cadence with key readouts and program milestones — alongside planned investments and a strategic acquisition (Apellis) expected to be accretive in 2027. Near‑term headwinds include timing/inventory lumpiness, material acquired IPR&D charges impacting near‑term EPS, increased R&D/SG&A investments and regulatory/clinical binary risks on pioneering programs. On balance, management portrayed confidence in execution, cash flow and future growth optionality.View all BIIB earnings summariesBIIB Revenue Breakdown
71.98% Product revenue
18.81% Revenue from anti-CD20 therapeutic programs
1.80% Alzheimer's collaboration revenue
7.41% Contract manufacturing, royalty and other revenue
BIIB Stock 12 Month Forecast
Average Price Target
$219.00
▲(23.48% Upside)
Technical Analysis
Ownership Overview
0.19% Insiders
36.39% Mutual Funds
21.47% Other Institutional Investors
14.14% Public Companies and Individual Investors